Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2967/jnumed.122.265291 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First-in-human results of terbium-161 [Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.
Lancet Oncol
August 2025
Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Elect
Background: Terbium-161 (Tb) emits beta-radiation similar to lutetium-177 (Lu), with additional radiation over ultra-short path lengths from Auger electrons. Tb has shown superior in-vitro and in-vivo efficacy compared with Lu. We aimed to evaluate the safety of [Tb]Tb-PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC).
View Article and Find Full Text PDFClinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [Tb]Tb-PSMA-I&T.
J Nucl Med
August 2024
Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
[Lu]Lu-PSMA is an effective class of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC); however, progression is inevitable. The limited durability of response may be partially explained by the presence of micrometastatic deposits, which are energy-sheltered and receive low absorbed radiation with Lu due to the approximately 0.7-mm mean pathlength.
View Article and Find Full Text PDFFrom Despair to Hope: First Arabic Experience of Lu-PSMA and Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer.
Cancers (Basel)
May 2024
Department of Diagnostic Radiology, King Hussein Cancer Center (KHCC), Amman 11941, Jordan.
The objective of this retrospective study is to assess the effectiveness and safety of two beta-emitting prostate-specific membrane antigen (PSMA) radioligands, [Lu]Lu and [161Tb]Tb, in heavily treated patients with metastatic castration-resistant prostate cancer (mCRPC). A total of 148 cycles of beta-emitting PSMA radioligand therapy were given to 53 patients at a specialized cancer care center in Amman, Jordan. This treatment was offered following the exhaustion of all prior treatment modalities.
View Article and Find Full Text PDF[Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [Lu]Lu-PSMA-617.
Theranostics
March 2024
Department of Nuclear Medicine, Saarland University, Medical Center, Homburg, Germany.
Evaluation of alternative radionuclides for use in prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is currently focusing on Tb, which may provide advantages by emitting additional Auger and conversion electrons. In this pilot study, we present preliminary dosimetry data for [Tb]Tb-PSMA-617 RLT in a direct comparison with [Lu]Lu-PSMA-617. Six patients with metastatic castration-resistant prostate cancer (mCRPC) underwent treatment with [Lu]Lu-PSMA-617 and subsequently - after inadequate response - with [Tb]Tb-PSMA-617.
View Article and Find Full Text PDFTb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer.
Nucl Med Mol Imaging
August 2023
Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria Australia.
Radiotheranostics with Lu-PSMA have changed the treatment paradigm in patients with prostate cancer, becoming the new standard in certain settings. Terbium-161 (Tb) has been recently investigated as a potential radionuclide for radiotheranostics in various types of cancer, including metastatic castration-resistant prostate cancer (mCRPC). The nuclear medicine team at King Hussein Cancer Center (KHCC) in Amman, Jordan, recently published the first-in-human SPECT/CT imaging results following a well-tolerated dose of Tb-PSMA radioligand therapy with no treatment-related adverse events, adding to the potential of radiotheranostics in prostate cancer.
View Article and Find Full Text PDF